By strategically harnessing the complementary mechanisms of MYC-targeted agents alongside conventional or immune-based therapies, oncology research stands to substantially enhance treatment effectiveness, overcome adaptive resistance, and ultimately improve patient outcomes in MYC-driven cancers. This evidence concerns the gene MYC and cancer.